Rabin Medical Center Announced They Will Initiate Clinical Trials to Test Feasibility of Exero Medical’s Wireless Anastomotic Sensor

RAYUS Radiology Quality Institute Distinguished Nationally by Centers for Medicare & Medicaid

Quality Institute Again Earns Certification as Provider-Led Entity for Advanced Diagnostic Imaging Guidance to Clinicians.

LX1550 Multiparameter Remote Monitoring Platform Receives FDA 510 (k) Approval: Reports LifeSignals

Further validation of ability to deliver continuous remote patient vital signs monitoring within both hospital and home settings.

U.S. News & World Report Names Tampa General Hospital as Best in Tampa Bay

This is the sixth consecutive year that Tampa General has been named by U.S. News & World Report as Tampa Bay's top hospital.

Israeli based Exero Medical, developer of a wireless sensor for early detection of anastomotic leaks following GI surgery, today announced that it will start its first clinical trial at the Rabin Medical Center to test the feasibility of its system. The clinical trial has been approved by the Institutional Review Board of Rabin Medical Center and Israel’s Ministry of Health.

Researchers at Rabin Medical Center will use Exero’s system to collect data from the sensor during low anterior resection surgery. The results of the trial will enable the company to refine its detection algorithms based on real-life data.

“Exero Medical addresses the $2 billion anastomotic leak (AL) market for which current approaches can only detect leaks post-op when the situation has become life-threatening for the patient,” said Dr. Erez Shor, CEO of Exero Medical. “Incidence and cost of AL is alarmingly high. Through early detection of anastomotic leaks, physicians can intervene earlier and save lives.”

Anastomotic leaks have a 6-10 percent occurrence rate post-operation in lower GI procedures and can lead to life-threatening complications, with substantial risk of mortality. There is currently no solution to address the high incidence of postoperative anastomotic leaks. The occurrence of AL is not a function of the surgeon’s skill or the equipment used but can happen to any patient following surgery.

“Currently, the risk of anastomotic leak after resection surgery is one of the fears keeping surgeons up at night. GI resection procedures to remove cancerous growths are performed on patients whose health is already fragile. The additional, potentially fatal risk of leaks requires an innovative solution,” explained Prof. Nir Wasserberg MD, Chairman of the Israeli Society of Colorectal Surgery and Director of the Division of Colorectal Surgery at Rabin Medical Center. “Exero has developed a platform that has the potential to provide surgeons with data they have never before had access to – real-time information on tissue healing. This will arm physicians with the insight they need to intervene before a patient’s status becomes catastrophic.”

Exero Medical’s sensor along with its proprietary machine learning algorithms is designed to monitor and analyze the surrounding tissue, sending live feedback to healthcare staff regarding the tissue healing progress.

Exero Medical is a portfolio company of MEDX Xelerator, an Israeli Innovation Authority incubator which is a joint initiative of Boston Scientific, Intellectual Ventures, MEDX Ventures and Sheba Medical Center.

spot_img

DON'T MISS

Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.